Generic Visudyne Availability

Visudyne is a brand name of verteporfin, approved by the FDA in the following formulation(s):

VISUDYNE (verteporfin - injectable;injection)

  • Manufacturer: VALEANT PHARMS INC
    Approval date: April 12, 2000
    Strength(s): 15MG/VIAL [RLD]

Has a generic version of Visudyne been approved?

No. There is currently no therapeutically equivalent version of Visudyne available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Visudyne. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
    Patent 5,707,608
    Issued: January 13, 1998
    Inventor(s): Liu; Ron
    Assignee(s): QLT PhotoTherapeutics, Inc.
    Liposomal compositions containing green porphyrins as photosensitizers are improved by enhancing the ratio of phospholipid to photosensitizer and by conducting the hydration an sizing of the liposomes in the composition at low temperature.
    Patent expiration dates:
    • August 2, 2015
  • Vision through photodynamic therapy of the eye
    Patent 5,756,541
    Issued: May 26, 1998
    Inventor(s): Strong; H. Andrew & Levy; Julia & Huber; Gustav & Fsadni; Mario
    Assignee(s): QLT Phototherapeutics Inc
    Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects,
    Patent expiration dates:
    • March 11, 2016
      ✓ 
      Patent use: USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
  • Method of activating photosensitive agents
    Patent 5,770,619
    Issued: June 23, 1998
    Inventor(s): Richter; Anna M. & Waterfield; Elizabeth & Levy; Julia G.
    Assignee(s): University of British Columbia
    A method of administering photodynamic therapy begins with administering to an animal an effective amount of a photosensitizing agent which is less than about one half of the usual clinical dose for the photosensitizing agent. Then, following a post injection interval which is less about one quarter of the usual post injection interval, an effective dose of light which is less than about one half of the usual clinical dose of light used in conjunction with the photosensitizing agent is administered to the animal.
    Patent expiration dates:
    • January 6, 2015
      ✓ 
      Patent use: USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
  • Use of green porphyrins to treat neovasculature in the eye
    Patent 5,798,349
    Issued: August 25, 1998
    Inventor(s): Levy; Julia & Miller; Joan W. & Gradoudas; Evangelos S. & Hasan; Tayyaba & Schmidt-Erfurth; Ursula
    Assignee(s): The General Hospital Corporation Quadra Logic Technologies, Inc. Massachuesetts Eye & Ear Infirmary
    Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.
    Patent expiration dates:
    • August 25, 2015
      ✓ 
      Patent use: USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)